The position the Company aspires to establish by FY2033 is to become a company that strongly turns the “value creation cycle” and continuously translates innovation into real-world solutions focusing on disease fields in oncology, psychiatry & neurology and others, and on modalities such as small molecules and regenerative medicine/cell therapy. By turning the value creation cycle, the Company will strategically deepen and expand these strengths as well as establish a distinctive global presence in order to contribute to the betterment of healthcare and fuller lives of people worldwide.



Important Notice
Showcase Sumitomo Pharma in a nutshell
Here you can search for the strengths of Sumitomo Pharma’s business, Sumitomo Pharma’s initiatives, and other information that interests you by selecting tags.
Strengths Sumitomo Pharma’s Three Strengths
- 1R&D Capabilities
- 2Human Resources
- 3Global Business Platforms
Press Releases
- Jun. 06, 2025 Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo’s Canadian Portfolio(PDF/175KB) Corporate
- May 30, 2025 Sumitomo Pharma and Novo Nordisk Pharma Enter into a Co-Promotion Agreement for Ozempic Subcutaneous Injection, a Treatment for Type 2 Diabetes, in Japan Licensing
- May 28, 2025 (Progress of disclosure matters) Notice Regarding a Company Split (Simplified Absorption-Type Company Split) of the Asian Business and the Execution of a Share Transfer Agreement and a Shareholders' Agreement with Marubeni Global Pharma Corporation Corporate
- May 19, 2025 Posted conference on FY2024 Financial Results and Reboot 2027 – Reboot for a Strong Sumitomo Pharma – [Webcast] Finances
- May 13, 2025 Presentation Material (Conference on FY2024 Financial Results and Reboot 2027 – Reboot for a Strong Sumitomo Pharma –)(PDF/4,377KB) Finances
Notices
- May 30, 2025 Posted Notice of Convocation of the 205th Annual Shareholders' Meeting Corporate
- May 27, 2025 Caution Regarding Suspicious Emails Impersonating the Company Others
- Jun. 28, 2024 Consolidated Financial Statements for Years ended March 31, 2024 and 2023 Finances
For the Press
Our latest press releases and other information for members of the press,
including various data sets and guidelines for their use.
-
Sustainability
Sumitomo Pharma defines the practice of its Mission, “To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide,” as Sustainability Management. To this end , Sumitomo Pharma is pursuing Sustainability Management through a variety of initiatives, including the development of innovative products and healthcare solutions, and contribution to the development of science.
-
About Us
Message from the President, corporate profile of Sumitomo Pharma, business activities, mid-term management plan, key locations and group companies, etc.
-
Investor Relations
Information for shareholders and investors of Sumitomo Pharma, including management policies, IR materials, and stock and shareholder-related information.